Citi analyst Jason Cassorla has opened a "positive Catalyst Watch" for Cano Health, citing his anticipating of an announcement for funding future growth. He believes the solvency risks for Cano are priced in at current levels and he sees near-term upside to shares on an announcement over the coming weeks and months of incremental external funding, a buyout, or the ability to self-fund operations for 2023 and beyond, said Cassorla, who maintains a Buy rating and $5 price target on Cano shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANO:
- BofA resumes Cano Health at Underperform, sees potential more guidance cuts
- Cano Health resumed with an Underperform at BofA
- Third Point sold Cano Health stake last week, Bloomberg reports
- Cano Health downgraded at Cowen with liquidity ‘now a plausible 2023 concern’
- Cano Health downgraded to Market Perform from Outperform at Cowen
